Results 171 to 180 of about 49,110 (259)

Bacterial Minicell‐Based Biohybrid Sub‐micron Swimmers for Targeted Cargo Delivery

Advanced Science, EarlyView.
Bacterial minicells, vesicles derived from engineered E. coli, offer promising sub‐micron scale biohybrid swimmers for targeted cargo delivery. Purified with over 99% efficiency while retaining motility, they are functionalized with MNPs for controlled movement.
Saadet Fatma Baltaci, Mukrime Birgul Akolpoglu, Irina Kalita, Victor Sourjik, Metin Sitti   +4 more
wiley   +1 more source

Integrated analysis of CD30 detection methodologies and synergistic drug combinations for optimizing brentuximab vedotin therapy in lymphoma. [PDF]

Clin Exp Med
Ye M, Wang T, Song Z, Liu X, Liu P, Zhang L, Tang G, He M, Liu N, Yang J.   +9 more
europepmc   +1 more source

Mortalin and PINK1/Parkin‐Mediated Mitophagy Represent Ovarian Cancer‐Selective Targets for Drug Development

Advanced Science, EarlyView.
Ovarian cancer patients with high levels of mortalin protein in their tumors have worse survival. The investigational drug SHetA2 interferes with mortalin's support of mitochondria. The resulting mitochondrial damage causes a process called mitophagy that contributes to how SHetA2 kills cancer cells. Noncancerous cells repair their mitochondria through
Vishal Chandra, Justin Garland, Rajani Rai, Donghua Zhao, Charuksha Walgama, Sadagopan Krishnan, Andrew T. Long, Tongzu Liu, Laura Adhikari, Doris M. Benbrook   +9 more
wiley   +1 more source

From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies

Advanced Science, EarlyView.
This review discusses emerging paradigms in CAR‐T cell therapy for solid tumors, emphasizing strategies to overcome therapeutic barriers through synthetic biology, immune engineering, and combinatorial approaches. It highlights advancements in logic gating, modulation of the immune microenvironment, and innovative cell designs, providing valuable ...
Yang Chen, Ran Ren, Lirong Yan, Yu Zhou, Ruokai Sun, Huicong Song, Hongfei Yan, Yongsheng Li   +7 more
wiley   +1 more source

Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. [PDF]

Trials
Ostrowska-Leśko M, Mądry R, Bobiński M.   +2 more
europepmc   +1 more source

Contribution of Prostaglandin E2‐Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood–Brain Barrier Crossing Celecoxib Derivative

Advanced Science, EarlyView.
Glioblastoma (GBM) is an aggressive brain cancer that often recurs and resists chemotherapy. This study found that a chemical called PGE2 causes surrounding brain cells (neurons) to become over‐excited, which makes GBM cells resistant to treatment. Researchers developed a new drug, “Compound 11,” which can cross into the brain and effectively block ...
Chih‐Jie Shen, Hsien‐Chung Chen, Chien‐Liang Lin, Amandeep Thakur, Raphael Onuku, I‐Chung Chen, Hao‐Yi Li, Kwang‐Yu Chang, Jian‐Ying Chuang, Wen‐Bin Yang, Hong‐Yi Lin, Yi‐Ru Shen, Jing‐Ping Liou, Wen‐Chang Chang, Tsung‐I Hsu   +14 more
wiley   +1 more source

Analysis of Cardiotoxicity and Risk Factors of Breast Cancer Chemotherapy Drugs: A Five-Year Single-Centre Retrospective Study in Early Breast Cancer. [PDF]

Drug Des Devel Ther
Ju F, Gu H, Yu L, Zhao G, Liu Y, Yin D, Niu J, Xue T, Yin C, Jiao L, Li C, Wu J, Ji Y.   +12 more
europepmc   +1 more source

Sono‐Controllable Janus Hydrogel Platform for Sequential Tumor Eradication and Bone Regeneration in Metastatic Breast Cancer

Advanced Science, EarlyView.
Sequential tumor eradication and bone regeneration remain a significant challenge for patients with breast cancer bone metastases. This study develops a novel Janus hydrogel platform, which can achieve tumor elimination and bone repair under the action of different ultrasound frequencies.
Yitong Li, Yunyun Liu, Chuyun Lou, Xuejun Chen, Ying Zhang, Hui Shi, Jiayi Qiu, Shen Zhang, Taixia Wang, Xiaowei Wang, Haohao Yin, Huixiong Xu, Yifeng Zhang   +12 more
wiley   +1 more source

Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives. [PDF]

Oncol Res
Carrano R, Zucca C, Cristina N, Grande M, Maggio EL, Bei R, Infante A, Focaccetti C, Lucarini V, Cifaldi L, Masuelli L, Mutti L, Palumbo C, Benvenuto M, Bei R.   +14 more
europepmc   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

Advanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang   +8 more
wiley   +1 more source